Caelyx [liposomal doxorubicin] in breast cancer in the elderly. Pegylated liposomal doxorubicin (Caelyx) as monotherapy in elderly patients with locally advanced and/or metastatic breast cancer.

Trial Profile

Caelyx [liposomal doxorubicin] in breast cancer in the elderly. Pegylated liposomal doxorubicin (Caelyx) as monotherapy in elderly patients with locally advanced and/or metastatic breast cancer.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2014

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 22 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top